JANIMINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JANIMINE is an oral small-molecule tablet approved in 1974 by Abbott with an unknown mechanism of action and indication profile. The drug's specific therapeutic class and patient population cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) signals potential team contraction and shift toward defensive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JANIMINE presents minimal career growth opportunity with zero linked job openings and approaching loss of exclusivity. Roles on this product focus on managing generic transition and brand legacy rather than expansion.
Brand ManagerField Sales Representative
Worked on JANIMINE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.